Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action

Curr Top Microbiol Immunol. 2022:440:31-70. doi: 10.1007/82_2021_233.

Abstract

Self-amplifying mRNAs derived from the genomes of positive-strand RNA viruses have recently come into focus as a promising technology platform for vaccine development. Non-virally delivered self-amplifying mRNA vaccines have the potential to be highly versatile, potent, streamlined, scalable, and inexpensive. By amplifying their genome and the antigen encoding mRNA in the host cell, the self-amplifying mRNA mimics a viral infection, resulting in sustained levels of the target protein combined with self-adjuvanting innate immune responses, ultimately leading to potent and long-lasting antigen-specific humoral and cellular immune responses. Moreover, in principle, any eukaryotic sequence could be encoded by self-amplifying mRNA without the need to change the manufacturing process, thereby enabling a much faster and flexible research and development timeline than the current vaccines and hence a quicker response to emerging infectious diseases. This chapter highlights the rapid progress made in using non-virally delivered self-amplifying mRNA-based vaccines against infectious diseases in animal models. We provide an overview of the unique attributes of this vaccine approach, summarize the growing body of work defining its mechanism of action, discuss the current challenges and latest advances, and highlight perspectives about the future of this promising technology.

Keywords: Infectious diseases; Self-amplifying mRNA; Synthetic vaccine.

MeSH terms

  • Animals
  • Antigens
  • Immunity, Cellular
  • RNA, Messenger / genetics
  • Virus Diseases*

Substances

  • RNA, Messenger
  • Antigens